GlobeNewswire by notified

Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022

Share

PRESS RELEASE

August 18, 2022

Today, on August 18, 2022, an extraordinarygeneral meeting was held in Saniona AB.A summary of the adopted resolution follows below. The resolution was adopted with the required majority of votes.

Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants

The extraordinary general meeting resolved in accordance with the proposal from the board of directors to adopt an employee option program for the company’s CEO and CFO.

The employee option program shall comprise a maximum of 2,129,821 employee options. Each employee option entitles the holders a right to acquire one new share in the company against cash consideration at an exercise price amounting to 130 per cent of the volume weighted average share price of the company’s share on Nasdaq Stockholm during the 10 trading days immediately prior to the extraordinary general meeting on 18 August 2022. The employee options shall be allotted without consideration and allotment shall take place no later than 31 December 2022. The allotted employee options will vest with 1/3 each on the date that falls 12, 24 and 36 months, respectively, following the date of allotment.

Allotted and vested employee options can be exercised during the period starting on the date that falls 3 years after the allotment date and ending on 31 December 2028. The board of directors has the right to limit the number of occasions during the exercise period when the employee options can be exercised.

In order to enable the company’s delivery of shares under the employee option program the extraordinary general meeting also resolved on a directed issue of warrants to the company or a subsidiary in the group. The warrants shall thereafter be transferred to the participants without consideration upon exercises of the employee options.

In the event all warrants that are issued in relation to the employee option program are exercised for subscription of shares, a total of 2,129,821 shares will be issued, which corresponds to a dilution of approximately 3.30 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of all warrants proposed to be issued in relation to the employee option program.

Malmö on August 18, 2022

Saniona AB (publ)

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

This information was submitted for publication, through the agency of the contact person set out above, at 16.30 CEST on August 18, 2022.

About Saniona
Saniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company’s most advanced product candidate, Tesomet™, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. These clinical trials are voluntarily paused due to funding limitations and Saniona is actively exploring partnering opportunities. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 has successfully completed a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

MT Højgaard Holding A/S: MT Højgaard Danmark to construct production facility for Novo Nordisk2.12.2022 11:27:08 CET | Press release

MT Højgaard Holding’s business unit MT Højgaard Danmark has entered a cooperation-based contract with Novo Nordisk for the construction of a production facility as well as modification and extension of existing buildings in Bagsværd. The project is executed in cooperation with Kemp & Lauritzen, and the total contract sum is estimated at DKK 1.2 billion of which MT Højgaard Danmark’s estimated share constitutes DKK 600 million. The project has been initiated immediately and is expected to be completed in the second half of 2024. The contract does not change MT Højgaard Holding’s previously announced 2022 outlook, but it will contribute significantly to the group’s long-term, sustainable development in the coming years. Contact: CEO Henrik Mielke and CFO Martin Solberg can be contacted on telephone +45 22 70 93 65. Attachment MTHH_Company announcement 2Dec22

MT Højgaard Holding A/S: MT Højgaard Danmark skal udføre produktionsbygning for Novo Nordisk2.12.2022 11:27:08 CET | pressemeddelelse

MT Højgaard Holdings forretningsenhed MT Højgaard Danmark har indgået en samarbejdsbaseret kontrakt med Novo Nordisk om opførelse af en produktionsbygning samt om- og tilbygning af eksisterende bygninger i Bagsværd. Opgaven udføres i samarbejde med Kemp & Lauritzen, og den samlede kontraktsum er estimeret til at udgøre 1,2 mia. kr., hvoraf MT Højgaard Danmarks andel er estimeret til at udgøre 600 mio. kr. Projektet er iværksat straks og forventes fuldført i 2. halvår 2024. Kontrakten ændrer ikke MT Højgaard Holdings udmeldte forventninger til 2022, men vil yde et væsentligt bidrag til koncernens langsigtede, bæredygtige udvikling i de kommende år. Yderligere oplysninger: Henvendelse til koncernchef Henrik Mielke og CFO Martin Solberg kan ske på telefon +45 22 70 93 65. Vedhæftet fil MTHH_Selskabsmeddelelse 2dec22

Colliers completes acquisition of Pangea2.12.2022 10:00:40 CET | Press release

TORONTO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) has completed its previously announced acquisition of a controlling interest in Pangea Property Partners (“Pangea”), a leading capital markets advisor in Sweden and Norway. Pangea becomes Colliers’ new company-owned operation in Norway and will merge with Colliers’ existing company-owned operations in Sweden. This transaction firmly positions Colliers as the dominant player in the Nordic region, building on our top-tier operations in Denmark and Finland. About Colliers Colliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 63 countries, our 18,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 27 years, our experienced leadership with significant inside ownership has delivered compound ann